Skip to main content
. 2020 Nov 26;26(3):577–585. doi: 10.1007/s10741-020-10057-7

Table 2.

Outcomes of the included studies

First author Bart Bart Hanna Giglioli Seker Costanzo Marenzi Costanzo
Year 2005 2012 2012 2011 2016 2007 2014 2015
Intervention group size 20 94 17 15 10 100 27 110
Control group size 20 94 19 15 20 100 29 111
Worsening HF in UF group 31 2 39 4
Worsening HF in UC group 28 7 63 3
Renal impairment in UF group 17 8 2 21 2
Renal impairment in UC group 14 6 1 17 2
Rehospitalization for HF in UF group 23 16 1 10
Rehospitalization for HF in UC group 24 28 14 22
Deaths in UF group 1 16 4 4 9 7 17
Deaths in UC group 0 13 4 2 11 11 14
Weight loss in UF group (kg) 2.5 5.7 ± 3.9 4.7 ± 3.5 5.0 ± 3.1 7.5 ± 5.5 10.7 ± 7.2
Weight loss in UC group (kg) 1.86 5.5 ± 5.1 1.0 ± 2.5 3.1 ± 0.75 7.9 ± 9.0 10.3 ± 9.2
Fluid removal in UF group (mL) 8415 7443 ± 4329 5215 ± 3406 11086 ± 1786 7872 ± 1829 4600 ± 2600 12900
Fluid removal in UC group (mL) 5375 7082 ± 4183 2167 ± 2380 10425 ± 3002 6882 ± 4221 3300 ± 2600 8900
UF – ultrafiltration, UC – usual care, AE – adverse events, RCT – randomized controlled trial, DM – diabetes mellitus, ACE – angiotensin-converting enzyme inhibitor, ARB – angiotensin II receptor blocker